Peijia Medical : VOLUNTARY ANNOUNCEMENT - Completion of Patient Enrollment for the Clinical Trial of TaurusElite

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Peijia Medical Limited

沛嘉醫療有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9996)

VOLUNTARY ANNOUNCEMENT

Completion of Patient Enrollment for the Clinical Trial of TaurusElite®

This announcement is made by Peijia Medical Limited (the "Company", together with its subsidiaries, the "Group") on a voluntary basis to provide the shareholders and potential investors with updated information in relation to the latest business and new product development of the Group.

The board (the "Board") of directors (the "Directors") of the Company is pleased to announce that by September 17, 2020, the Company has completed the patient enrollment process for the clinical trial of TaurusElite®, the second-generation transcatheter aortic valve replacement ("TAVR") product independently developed by the Company. Compared to TaurusOne®, the Company's first-generation TAVR device and Core Product (within the meaning ascribed thereto in Chapter 18A of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited), TaurusElite® contains a delivery catheter system (DCS) with retrieving function, allowing physicians to retrieve the prosthetic aortic valve (PAV) if the initial release position is not ideal, thereby further increasing the safety of the product.

The Company initiated a multi-center clinical trial for TaurusElite® in December 2019, and on September 8, 2020, TaurusElite® was recognized as an "Innovative Medical Device" by the National Medical Products Administration of the PRC (NMPA), and is therefore eligible for an expedited approval process.

Looking ahead, the Company will carry forward its ongoing clinical programs, continue to strengthen its in-house research and development capabilities, and will seek deeper cooperation and partnership around the globe, to advance and expedite the research and development of other product candidates in pipeline.

- 1 -

THE COMPANY MAY NOT BE ABLE TO ULTIMATELY DEVELOP AND MARKET TAURUSONE® AND TAURUSELITE® SUCCESSFULLY. SHAREHOLDERS AND POTENTIAL INVESTORS OF THE COMPANY ARE ADVISED TO EXERCISE DUE CARE WHEN DEALING IN THE SHARES OF THE COMPANY.

By order of the Board

Peijia Medical Limited

Dr. Yi Zhang

Chairman and Executive Director

Hong Kong, September 18, 2020

As of the date of this announcement, the Board comprises Dr. Yi Zhang, Ms. Ping Ye Zhang and Ms. Hong Ye as executive Directors, Dr. Zhiyun Yu, Mr. Jifeng Guan, Mr. Fei Chen, Mr. Jun Yang as non-executive Directors, and Dr. Stephen Newman Oesterle, Mr. Robert Ralph Parks, Mr. Wayne Wu and Mr. Wai Ming Yip as independent non-executive Directors.

- 2 -